Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last?
Adma Biologics (ADMA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Does Adma Biologics (ADMA) Have the Potential to Rally 51.75% as Wall Street Analysts Expect?
The mean of analysts' price targets for Adma Biologics (ADMA) points to a 51.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
ADMA Biologics Inc (ADMA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ADMA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Here is What to Know Beyond Why ADMA Biologics Inc (ADMA) is a Trending Stock
Adma Biologics (ADMA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential
ADMA Biologics shows robust revenue growth, driven by its innovative IVIG product, ASCENIV, which targets primary humoral immunodeficiency and includes RSV antibodies. Q4 earnings reveal a 59% year-over-year revenue increase, with strong gross profit margins and minimal R&D expenses, highlighting ADMA's efficient operations. Financial health is solid with $103.147 million in cash and manageable liabilities, supporting long-term growth and investment potential.
Wall Street Analysts Predict a 39.08% Upside in Adma Biologics (ADMA): Here's What You Should Know
The mean of analysts' price targets for Adma Biologics (ADMA) points to a 39.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains?
Adma Biologics (ADMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Why Adma Biologics (ADMA) Outpaced the Stock Market Today
In the most recent trading session, Adma Biologics (ADMA) closed at $18.67, indicating a +1.3% shift from the previous trading day.
Will ADMA Biologics Stock Continue Its Momentum in 2025?
ADMA continues to maintain momentum in 2025 after its stupendous performance in 2024. Strong demand for Asceniv should fuel growth.
